CRYOPORT INC (CYRX)
Health Care · Cell and gene therapy supply chain / temperature-controlled life sciences logistics · NASDAQ
Cryoport is the leading provider of end-to-end temperature-controlled supply chain solutions specifically built for cell and gene therapies, from preclinical development through global commercialization.
What CRYOPORT INC does
Cryoport is a leading provider of integrated, temperature-controlled supply chain solutions for the life sciences, with specialization in cell and gene therapy (CGT). The company operates through three business units—Cryoport Systems (BioLogistics, BioServices, and cryopreservation), CryoGene (long-term biostorage), and MVE Biological Solutions (cryogenic equipment manufacturing)—delivering end-to-end Chain of Compliance solutions for clinical trials and commercialized therapies. As of December 2025, Cryoport supported 760 clinical trials and 20 commercially approved cell and gene therapies.
Themes: ["Cell and gene therapy supply chain","Temperature-controlled logistics","Biopharmaceutical distribution","Clinical trial support","Cryogenic storage and preservation","Life sciences infrastructure","Chain of compliance / regulatory compliance","Digital health logistics"]
Fundamentals
- Price$15.72 as of 2026-07-09 close
- Market cap$791M as of 2026-07-10
- 1-year return+109.9% as of 2026-07-09 close
- P/E10.40 as of 2026-07-10
- Net margin+41.6% as of 2026-07-10
- Gross margin+47.2% as of 2026-07-10
- ROE+15.0% as of 2026-07-10
- Debt / equity0.38 as of 2026-07-10
- Revenue growth (YoY)-14.8% as of 2026-07-10
- Revenue CAGR (3y)-9.4% SEC XBRL
- Beta1.89 as of 2026-07-10
Key risks (from latest filing)
["Concentration risk: Dependent on CGT market growth and customer adoption; revenue declined 14.85% YoY as of mid-2026","Operational complexity: Managing global temperature-controlled supply chain requires stringent regulatory compliance and specialized infrastructure; loss from continuing operations in Q1 2026","Integration and divestiture execution: Recently divested CRYOPDP specialty courier business to DHL; reliance on new partnership to maintain service delivery in EMEA and APAC regions"]
Competitors & peers
- World Courier (specialty life sciences logistics)
- DHL Supply Chain (after acquiring CRYOPDP specialty courier operations)
- Agility (temperature-controlled logistics)
- Lonza (cell and gene therapy CDMO and supply chain)
- FUJIFILM Diosynth (cell and gene therapy manufacturing and logistics)
Fundamentals: Finnhub, as of 2026-07-10. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-09.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date.